文献速递皮肤肿瘤

组织特异性PD-L1表达评分在黑色素瘤辅助免疫治疗中的差异预测价值

Differential predictive value of tissue-specific PD-L1 expression scores in adjuvant immunotherapy of melanoma.
PubMed 文献 · J Eur Acad Dermatol Venereol · 2024-06-15

该回顾性观察研究纳入243例II-IV期黑色素瘤患者,其中104例可分析,评估辅助抗PD-1治疗前肿瘤组织PD-L1表达(ICS、TPS、CPS)与无复发生存(RFS)的关联。结果显示原发肿瘤中ICS阳性(CO 1%)与RFS改善显著相关(HR 0.22),转移灶中TPS阳性(CO 1%)与RFS改善独立显著相关(HR 0.37),提示PD-L1预测价值具有组织特异性。

要点

  • 原发肿瘤中免疫细胞PD-L1阳性(CO 1%)与辅助抗PD-1后RFS改善显著相关(HR 0.22)。
  • 转移灶中肿瘤细胞PD-L1阳性(CO 1%)与RFS改善独立显著相关(HR 0.37)。
  • 不考虑组织来源时,ICS、TPS、CPS阳性在不同截断值下均未显示预测RFS的关联。

核心结论

  • PD-L1肿瘤组织表达可能作为黑色素瘤辅助ICI治疗反应分层的预测生物标志物,但需注意分析组织的来源。

研究设计与样本

  • 回顾性观察研究,在汉堡大学皮肤癌症中心收集243例II-IV期黑色素瘤患者抗PD-1辅助ICI治疗前的肿瘤组织。
  • PD-L1表达由独立病理医师量化评估免疫细胞(ICS)、肿瘤细胞(TPS)和联合(CPS)评分,并与不同截断值下的RFS相关。
  • 共104例患者符合分析条件。

主要发现

  • 不考虑组织来源时,ICS、TPS和CPS阳性在不同截断值下均未显示与RFS结局的预测关联。
  • 原发肿瘤中,ICS在截断值1%时阳性显示RFS显著改善(HR 0.22)。
  • 转移性肿瘤组织中,TPS在截断值1%时阳性与RFS改善显著且独立相关(HR 0.37)。

关键数值与推荐

  • 原发肿瘤ICS阳性截断值1%:RFS改善HR 0.22。
  • 转移灶TPS阳性截断值1%:RFS改善独立相关HR 0.37。
  • 约25%-30%的患者仍在1年内复发。

临床怎么用

  • PD-L1表达可能用于辅助ICI治疗反应分层,但解读时应考虑肿瘤组织来源。
  • 原发肿瘤中关注免疫细胞PD-L1,转移灶中关注肿瘤细胞PD-L1。

局限性

  • 结果为回顾性单中心数据,需在多中心队列中验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Adjuvant treatment of stage II-IV melanoma with PD-1-based immune checkpoint inhibitors (ICI) has improved relapse-free survival (RFS) and has therefore become a standard-of-care treatment option. Approximately 25%-30% of patients still recur within 1 year. Predictive biomarkers reflecting real-world data are desired. The predictive relevance of tumour tissue PD-L1 expression in the adjuvant setting remains inconclusive. OBJECTIVES: This retrospective, observational study was conducted to evaluate the value of PD-L1 expression scores in different tumour tissue locations in predicting response towards adjuvant immunotherapeutic treatment. METHODS: Tumour tissue taken prior to anti-PD-1 adjuvant ICI in 243 stage II-IV melanoma patients was collected at University Skin Cancer Center Hamburg. PD-L1 expression was evaluated on immune cells (ICS), tumour cells (TPS) and combined (CPS). Scores were determined by independent pathological physician quantification and correlated with therapy outcome at different cut-off (CO) levels (relapse-free survival, RFS) for different tumour tissue locations (primary tumour, metastases). RESULTS: A total of 104 patients were eligible for analysis. Positivity of ICS, TPS and CPS showed no predictive RFS outcome association at different CO levels when analysed irrespective of tissue origin. In primary tumours, ICS at CO 1% showed a significantly improved RFS upon positivity (HR 0.22). In contrast, positivity to TPS (CO 1%) correlated significantly and independently with improved RFS when evaluated in metastatic tumour tissue specimens (HR 0.37). CONCLUSIONS: PD-L1 tumour tissue expression may serve as a predictive biomarker for adjuvant ICI treatment response stratification in melanoma, but caution should be spent on the origin of tumour tissue analysed. The cell-type relevant for the predictive value of PD-L1 expression is tissue-specific with immune cells being important in primary tumours while tumour cells are key in metastases. The present results should be validated in a multicentre cohort.

来源:J Eur Acad Dermatol Venereol,查看原文。版权归原作者所有。

引用

  1. Geidel G, Parnian N, Meß C, et al. Differential predictive value of tissue-specific PD-L1 expression scores in adjuvant immunotherapy of melanoma. J Eur Acad Dermatol Venereol. 2024. PMID: 38877773. doi:10.1111/jdv.20177

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。